Metabolomics Signature Can Predict GDM to T2DM Transition

Share this content:
Metabolomics Signature Can Predict GDM to T2DM Transition
Metabolomics Signature Can Predict GDM to T2DM Transition

THURSDAY, June 30, 2016 (HealthDay News) -- A metabolomics signature can predict the transition from gestational diabetes mellitus (GDM) to type 2 diabetes (T2D), according to a study published online June 23 in Diabetes.

Amina Allalou, from the University of Toronto, and colleagues enrolled a prospective cohort of 1,035 women with GDM pregnancy at six to nine weeks postpartum and screened them for two years for T2D.

The researchers found that 113 of the 1,010 women without T2D at baseline progressed to T2D within two years, and another 17 developed T2D between two and four years. Metabolomics were conducted with baseline fasting plasma in a nested case-control study involving 122 incident T2D cases matched to non-cases by age, pre-pregnancy body mass index, and race/ethnicity. Twenty-one metabolites that differed significantly by incident T2D status were identified. Machine learning optimization was able to predict T2D incidence with a discriminative power of 83.0 and 76.9 percent in the training set and an independent testing set, respectively.

"Our metabolomics signature predicted T2D incidence from a single fasting sample," the authors write. "This study represents the first metabolomics study of the transition from GDM to T2D validated in an independent testing set, facilitating early intervention."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »